Company: ERAS
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103868
Chunk: 22

Company: Erasca, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 22
---
, and representations made, by management and the Company’s independent registered public accounting firm. The Company’s independent registered public accounting firm also provided the Audit Committee with a formal written statement required by PCAOB Rule 3526 (Communications with Audit Committees Concerning Independence) describing all relationships between the independent registered public accounting firm and the Company, including the disclosures required by the applicable requirements of the PCAOB regarding the independent registered public accounting firm’s communications with the Audit Committee concerning 13

independence. In addition, the Audit Committee discussed with the independent registered public accounting firm its independence from Erasca, Inc. The Audit Committee also considered whether the independent registered public accounting firm’s provision of certain other non-audit related services to the Company is compatible with maintaining such firm’s independence.

Based on the reviews and discussions referred to above, the Audit Committee recommended to the Board that the audited consolidated financial statements be included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The Audit Committee and the Board also have recommended, subject to stockholder approval, the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for 2025.

This report of the Audit Committee is not “soliciting material,” shall not be deemed “filed” with the SEC and shall not be incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent that we specifically incorporate this information by reference, and shall not otherwise be deemed filed under such acts.

The foregoing report has been furnished by the Audit Committee.

**Respectfully submitted,

Audit Committee

Alexander W. Casdin, Chair

Julie Hambleton, M.D.

Jean I. Liu, J.D.**

<div align='center'>14</div>

Executive Officers The following table identifies our executive officers as of April 28, 2025:

| Name                           |     | Age |    |     | Position                                                       |
| Jonathan E. Lim, M.D.          |     |     | 53 |     | Chairman of the Board, Chief Executive Officer, and Co-Founder |
| David M. Chacko, M.D.          |     |     | 42 |     | Chief Financial Officer and Chief Business